Human medicines European public assessment report (EPAR): Tesavel, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 10/01/2008, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, von Willebrand Diseases, Date of authorisation: 31/08/2018, Revision: 8, Status: Authorised

Committee for Orphan Medicinal Products (COMP): 11-13 July 2023, European Medicines Agency, Amsterdam, the Netherlands, from 11/07/2023 to 13/07/2023

Human medicines European public assessment report (EPAR): Apealea, paclitaxel, Ovarian Neoplasms, Date of authorisation: 20/11/2018, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Januvia, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 20/03/2007, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib, Alopecia Areata, Date of authorisation: 15/09/2023, Status: Authorised

Questions and answers for biological medicinal products

Joint EMA-ECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA, Online, 14:30 – 15:00 Amsterdam time (CEST), from 21/09/2023 to 21/09/2023

Human medicines European public assessment report (EPAR): Lumeblue (previously known as Methylthioninium chloride Cosmo), methylthioninium chloride, Colorectal Neoplasms;Colonoscopy, Date of authorisation: 19/08/2020, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Epilepsy;Anxiety Disorders;Neuralgia, Date of authorisation: 05/07/2004, Revision: 61, Status: Authorised